Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number,...